Actively Recruiting
Phase II Study of Epcoritamab and Lenalidomide for Treating Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Led by Reem Karmali · Updated on 2026-07-08
34
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of epcoritamab and lenalidomide in treating patients with immunodeficiency-related large B-cell lymphoma that is refractory or has relapsed. This phase II trial aims to assess how well this combination works in patients who cannot receive chemotherapy, focusing on response rates, survival, safety, and immune system changes. Participants receive epcoritamab as a subcutaneous injection weekly in the first cycle, then on specific days in cycles 2 to 12. Lenalidomide is given orally on days 1 to 21 of each 28-day cycle, continuing for up to 12 months unless the disease progresses or side effects become unacceptable. Patients undergo PETCT scans and blood sample collections during the study, with MRI possibly performed during screening. Throughout the study, participants are monitored for treatment response, survival, and safety up to 24 months. Researchers also assess immune cell changes and patient-reported symptoms using questionnaires. Follow-up visits occur 30 days after treatment completion, then at 12, 18, and 24 months, allowing a total participation duration of about two years.
CONDITIONS
Brief Title
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Research Team
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
